Related by context. All words. (Click for frequent words.) 66 gm dl 64 leukocyte count 63 nondiabetic patients 63 μg d 63 mL/min/#.# m 2 62 epoetin alpha 62 Serum creatinine 62 μg L 62 glomerular filtration 61 euthyroid 61 μg mL 61 cTnI 61 μmol L 61 elevated troponin 61 HbA 1c levels 61 urine albumin 61 serum sodium levels 61 hemodynamic variables 61 #OHD 61 NYHA functional class 61 QTcF 61 arterial oxygen saturation 60 pmol L 60 NNT = 60 μg kg 60 Plasma concentrations 60 hemoglobin Hb 60 serum lactate 60 normoxic 60 % CI #.#-#.# [003] 60 glycosylated hemoglobin levels 60 PSA nadir 60 hemoglobin concentration 59 mCi 59 antibody titer 59 SGPT 59 1c HbA 1c 59 blood glucose concentrations 59 tipranavir r 59 HbA1C levels 59 dimeglumine 59 aminotransferase 59 serum ALT 59 abacavir Ziagen 59 serum TSH 59 nicardipine 59 μg liter 59 P = .# 59 CI -#.# 59 preoperative PSA 59 serum concentrations 59 hepatorenal syndrome 59 neutrophil counts 59 serum creatinine levels 59 nmol 59 IOP lowering 59 hemoglobin concentrations 59 insulin glulisine 59 g dl 59 iPTH 58 anemia hemoglobin 58 serum albumin 58 Hb A1C 58 hemoglobin hematocrit 58 fasting triglycerides 58 serum urate 58 Fasting plasma glucose 58 aspartate aminotransferase 58 K DOQI 58 mEq L 58 multivariable adjusted 58 mcg mL 58 monophasic 58 tertiles 58 % CI #.#-#.# [008] 58 AUC0 58 Febrile neutropenia 58 mcg BID 58 p ≤ 58 hours postdose 58 titrated glipizide 58 lactate dehydrogenase LDH 58 alanine aminotransferase 58 creatinine ratio 58 bronchial hyperresponsiveness 58 perioperatively 58 AST ALT 58 deep venous thromboses 58 elevated LDH 58 urodynamic parameters 58 timepoints 58 mL/min/#.# m2 58 bronchoalveolar lavage 58 troponin T 58 interquartile range 58 serum cortisol 58 hemodilution 58 mIU L 58 elevated transaminases 58 pretest probability 58 Masimo noninvasive 58 efficacy evaluable 58 pg ml 58 ß blockers 58 serum uric acid 57 triacylglycerol concentrations 57 serum LDL cholesterol 57 g dL 57 alanine aminotransferase ALT 57 #.#mg/dL 57 PaO 2 57 artery stenosis 57 thrombocytopenic 57 ventilatory 57 % CI #.#-#.# [007] 57 P ≤ 57 coronary stenosis 57 atazanavir ritonavir 57 4mg/kg 57 piperacillin tazobactam 57 anagrelide 57 milliliters mL 57 hemoglobin A1c levels 57 tertile 57 colorectal adenoma 57 β blockers 57 baseline LDH 57 hsCRP levels 57 BENICAR HCT 57 otamixaban 57 pT3 57 baseline Hb 57 mmol l 57 plasma folate 57 sodium nitroprusside 57 postintervention 57 diastolic blood pressures 57 intracranial hemorrhage ICH 57 intracerebral haemorrhage 57 leukocytosis 57 p = .# [002] 57 atorvastatin #mg 57 HER2 expression 57 glycated hemoglobin levels 57 serum aminotransferase levels 57 urinary iodine 57 achieved CCyR 57 CK MB 57 μg dL 57 mmHg diastolic 57 lymphocytosis 57 mcg QD 57 thyroid carcinoma 57 NIHSS 57 -#.# ± [002] 57 preterm neonates 57 corticosteroid dose 57 specific antigen PSA 57 μg ml 57 serum estradiol 57 intravenous diuretics 57 abacavir lamivudine 57 intact parathyroid hormone 56 HBeAg negative patients 56 sub maximal 56 detemir 56 doxorubicin docetaxel 56 anti Xa 56 mIU ml 56 extensive metabolizers 56 urinary N telopeptide 56 elevated creatinine 56 REYATAZ r arm 56 mL kg 56 p = NS 56 lowest tertile 56 p = .# [001] 56 neutrophil count 56 parasitemia 56 serum bicarbonate 56 fluticasone salmeterol 56 SGRQ 56 isolated systolic hypertension 56 intravenous bolus 56 estimated GFR 56 lactate dehydrogenase 56 Hematocrit 56 lymphocyte count 56 dalteparin 56 BPS IC 56 #mg/dL [002] 56 Platelet counts 56 T1a 56 statistically significant p = 56 myocardial necrosis 56 extracapsular extension 56 ALT elevations 56 recurrent venous thromboembolism 56 plasma homocysteine 56 ml min 56 serum urate levels 56 triglyceride concentrations 56 plasma triglycerides 56 certolizumab 56 methacholine challenge 56 ng dL 56 thyroglobulin 56 biochemical relapse 56 -#.# log# 56 intima media thickness 56 lymphocyte counts 56 bolus dose 56 oral antidiabetic medication 56 nadroparin 56 serum homocysteine 56 dose Iluvien 56 antigen PSA levels 56 HOMA IR 56 leucopenia 56 #dhTxB# 56 mmol kg 56 tracheal intubation 56 folate concentrations 56 HbA 1c 56 PCWP 56 Stent thrombosis 56 CYP#D# inhibitor 56 ALT elevation 56 sUA 56 bFGF 56 endothelium dependent 56 #.#/#.# mmHg [001] 56 intracoronary 56 interleukin IL -6 56 ketorolac 56 LV dysfunction 56 isoprostane 56 ghrelin concentrations 56 lispro 56 hyperphenylalaninemia HPA due 56 p = #.# [003] 56 lumbar spine BMD 56 eosinophil count 56 pT2 56 PASI scores 56 aminotransferase ALT 56 nitroprusside 56 seropositivity 56 spine BMD 56 albumin excretion 56 aPTT 56 postdose 56 #mg/day [001] 56 mg/m2 dose 55 highest tertile 55 serum lipid levels 55 umol L 55 tissue oxygenation 55 Hypotension 55 undetectable viral 55 prostate cancer CaP 55 transaminase elevations 55 uM 55 Cmax 55 MMSE score 55 platelet reactivity 55 SpCO 55 oxygen saturation SpO2 55 isoproterenol 55 serum phosphate 55 liver histology 55 Viral load 55 glulisine 55 Abstract P# [002] 55 hyperresponsiveness 55 inhaled iloprost 55 glycosylated hemoglobin HbA1c 55 total thyroidectomy 55 hemoglobin A1c HbA1c 55 K DOQI guidelines 55 osmolality 55 bioavailable testosterone 55 mol L 55 gene polymorphism 55 HIV HCV coinfected 55 corrected QT interval 55 creatine phosphokinase 55 glomerular filtration rate 55 intraobserver 55 6mg 55 noninferior 55 Hgb 55 atherogenic dyslipidemia 55 HBsAg 55 Postoperatively 55 mild renal insufficiency 55 intravascular hemolysis 55 ug kg 55 GH deficiency 55 deoxy 55 salmeterol fluticasone 55 pulmonary capillary wedge 55 intermittent dosing 55 creatine kinase MB 55 vasopressor 55 systemic hypotension 55 CrCl 55 CC genotype 55 pg mL 55 MBq 55 acetazolamide 55 postoperative AF 55 SCr 55 plasma leptin 55 tracer uptake 55 serum retinol 55 ovarian carcinoma 55 QT Prolongation 55 Hb A1c 55 inversely associated 55 sitosterol 55 serum triglycerides 55 #ng/ml 55 PRADAXA #mg 55 isoenzyme 55 XIENCE V demonstrated 55 relapsed MM 55 stent binary restenosis 55 serum calcium levels 55 Pulse CO Oximeter 55 serum phosphorus levels 55 confidence interval #.#-#.# 55 nmol liter 55 leukocyte counts 55 ml kg 55 clevidipine 55 binary restenosis 55 aspartate aminotransferase AST 55 atrioventricular block 55 HbA1C 55 cardiac troponin T 55 ATV RTV 55 tolterodine ER 55 transdermal estradiol 55 Fasting blood glucose 54 ASCUS 54 homocysteine concentrations 54 plasma cortisol 54 carotid bruit 54 MADRS score 54 alkaline phosphatase 54 microvessel density 54 fractional shortening 54 gadobutrol 54 prospectively defined 54 Creatinine 54 poor metabolizers 54 complete cytogenetic response 54 IU ml 54 serum magnesium 54 morphometric vertebral fractures 54 MULTAQ 54 elevated ALT 54 transferrin saturation 54 echocardiographic parameters 54 brachial artery flow 54 moderate renal impairment 54 hypoperfusion 54 hepatic enzyme 54 cardiac repolarization 54 IFN alfa 54 cinacalcet 54 GnRH agonist 54 activated partial thromboplastin 54 systolic dysfunction 54 nitrofurantoin 54 subcutaneous insulin 54 Infusion Reactions Severe 54 gross hematuria 54 plasma renin 54 Hb 54 salmeterol fluticasone propionate 54 mm Hg systolic 54 dual endothelin receptor antagonist 54 periprocedural 54 rebleeding 54 CsA 54 exhaled NO 54 urinary albumin 54 macroalbuminuria 54 prespecified 54 oxycodone CR 54 postprandial blood glucose 54 Elevated serum 54 urolithiasis 54 posttransplant 54 thyrotropin 54 paricalcitol 54 myocardial infarctions MIs 54 cefazolin 54 adjuvant cisplatin 54 acromegalic patients 54 zoledronate 54 serum calcium 54 bronchoalveolar lavage fluid 54 clinically meaningful improvement 54 serum phosphate levels 54 dopamine partial agonist 54 radiotherapy RT 54 cardiac perfusion 54 fasting plasma glucose FPG 54 reinfarction 54 severe exacerbations 54 PREZISTA r arm 54 obstructive CAD 54 intravenous thrombolysis 54 #Gy 54 hyperhomocysteinemia 54 antithymocyte globulin 54 atheroma volume 54 moderately emetogenic 54 haematologic 54 #.#mmol L [002] 54 interobserver agreement 54 serum ferritin 54 chemoradiation therapy 54 ritonavir boosted lopinavir 54 lipid elevations 54 undetectable HBV DNA 54 anastomotic leak 54 F FDG PET 54 Visual Analogue Scale VAS 54 peritumoral 54 baseline HbA1c 54 beta blocker therapy 54 erythrocyte sedimentation rate 54 prostate carcinoma 54 oral anticoagulation 54 plasma glucose levels 54 OGTT 54 NPH insulin 54 dyslipidaemia 54 mean corpuscular volume 54 procalcitonin 54 nonobese 54 bolus injection 54 metastatic lymph nodes 54 adrenomedullin 54 Thrombolysis 54 Secondary endpoints include 54 biphasic insulin aspart 54 advanced adenoma 54 serum lipid 54 FDA defined valvulopathy 54 Secondary endpoints included 54 microbiologically evaluable 54 antitrypsin 54 sinus bradycardia 54 serum PTH 54 serum IGF 54 angiographically 54 hemodynamic parameters 54 CCyR 54 KRAS mutations occur 54 TURBT 54 overt nephropathy 54 NCEP ATP III 54 MGd 54 fluvastatin 54 mCi kg 54 Primary endpoints 54 maximal dose 54 serum triglyceride levels 54 perioperative mortality 54 octreotide LAR 54 CR nPR 54 PEG IFN 53 symptomatic intracranial 53 mm3 53 CTEPH 53 Hb levels 53 HBeAg 53 tacrolimus ointment 53 intraperitoneally 53 ≥ 53 nonmetastatic 53 dosing cohort 53 diastolic BP 53 BMI z 53 macular thickness 53 HSCT 53 matrix metalloproteinase MMP 53 dose atorvastatin 53 thetreatment 53 μg g 53 definite stent thrombosis 53 pamidronate 53 desvenlafaxine succinate 53 plasma lipids 53 TIMP 1 53 intravenous bolus injection 53 tHcy 53 rhGH 53 endothelial activation 53 serum sodium 53 adenoma recurrence 53 steroidogenic 53 nonischemic 53 Heavy menstrual bleeding 53 Alanine 53 IDDM 53 adiponectin concentrations 53 postop 53 elevated hsCRP 53 macrovascular events 53 SUVmax 53 epithelial ovarian cancer 53 viral titers 53 ALT AST 53 fructosamine 53 Nebulized 53 bisoprolol 53 posttreatment 53 Fasting glucose 53 remifentanil 53 polymyxin B 53 foveal thickness 53 femoral neck fracture 53 submaximal exercise 53 DAS# CRP 53 statistical significance p 53 fosamprenavir 53 aminotransferases 53 LVEF 53 mycophenolate 53 thromboxane A2 53 daily subcutaneous injections 53 carotid artery intima media 53 rt PA 53 SCIg 53 polyp recurrence 53 hematological parameters 53 diabetic hypertensive 53 infarct size 53 T2 lesion volume 53 carotid plaque 53 heFH 53 exhaled nitric oxide 53 darbepoetin alpha 53 Oximeter 53 genotypic resistance 53 Myoglobin 53 Ejection Fraction 53 #mmHg [001] 53 BARACLUDE ® 53 serum IgE 53 SpHb 53 serum thyroglobulin 53 baseline FEV 53 glycated hemoglobin HbA1c 53 LDB CPR 53 crossclamp 53 Exclusion criteria 53 locoregional recurrence 53 blood phenylalanine Phe 53 liposome formulation 53 antiangiogenic therapy 53 arterial elasticity 53 salivary cortisol 53 inotropic 53 diabetic polyneuropathy 53 XIENCE V PROMUS Stent 53 creatinine levels 53 thromboembolic complications 53 dose cohort 53 lipid lowering agents 53 SGOT 53 mmol liter 53 endoscopic resection 53 STRIDE PD 53 HBeAg seroconversion 53 prospectively stratified 53 FDG uptake 53 reintervention 53 hypothalamic amenorrhea 53 receiving VICTRELIS 53 thromboprophylaxis 53 cranial irradiation 53 postprocedure 53 STEMI ST 53 calculated creatinine clearance 53 systemic corticosteroid 53 D Dimer 53 serum insulin 53 insulin detemir 53 postprandial insulin 53 VLBW infants 53 creatine kinase 53 HBV DNA levels 53 hematopoietic cancers 53 radical prostatectomy RP 53 EpCAM expression 53 cerebral vasospasm 53 serum glucose 53 NSTE ACS 53 peripheral insulin sensitivity 53 advanced adenomas 53 TAVR 53 reticulocytes 53 Lipitor #mg 53 cytochrome oxidase 53 total cholesterol triglycerides 53 #mg dose [002] 53 resynchronization therapy 53 atrial pacing 53 #β estradiol 53 Diastolic pressure 53 6MWD 53 NIHSS score 53 Hypoglycaemia 53 achieved ACR# 53 achieved statistical significance 53 d dimer 53 COPD exacerbation 53 μg dl 53 Excretion 53 myeloperoxidase 53 Retreatment 53 segment binary restenosis 53 inflammatory biomarkers 52 nondiabetic subjects 52 hydroxyvitamin D concentrations 52 serum phosphorous 52 serum potassium 52 arterial thromboembolic events 52 cough dyspnea 52 nmol L 52 maternal serum 52 containing abacavir 52 hydroxy vitamin D 52 noninferiority 52 mCRPC 52 serum HBV DNA 52 #/#mmHg 52 D dimer 52 ng mL 52 corticosteroid dexamethasone 52 TRUS 52 hsCRP 52 suboptimal adherence 52 Homocysteine levels 52 noncardiac 52 Preoperatively 52 ICD shocks 52 antiphospholipid antibodies 52 plasma renin activity 52 F FDG uptake 52 autonomic dysfunction 52 symptomatic intracranial hemorrhage 52 kg -1 52 KDOQI 52 murine model 52 neutropenic sepsis 52 8 OHdG 52 NovoMix ® 52 GI toxicity 52 FDG-PET/CT 52 intracavitary 52 methylmalonic acid 52 striatal dopamine 52 ACE Inhibitor 52 statin monotherapy 52 HAART initiation 52 venous thromboembolic disease 52 confidence intervals CIs 52 DLCO 52 lupus anticoagulant 52 hydronephrosis 52 serum IgG 52 serum phosphorus 52 serum bilirubin 52 Legg Calvé Perthes disease 52 neurodevelopmental impairment 52 db db mice 52 troponins 52 creatinine clearance 52 inhibin 52 BENICAR 52 mg kg dose 52 intraocular pressure IOP 52 sitaxsentan 52 triiodothyronine 52 COHb 52 hypophosphatemia 52 improves glycemic 52 granulocyte 52 capillary density 52 chloride secretion 52 hypoxemia 52 IFN beta 52 rFVIIa 52 Non inferiority 52 graft occlusion 52 ibandronate 52 interferon ribavirin 52 Ki# 52 silent ischemia 52 LPV r 52 patientswith 52 antibody titers 52 ischemia induced 52 left ventricular systolic 52 nmol L. 52 cobalamin 52 hip BMD 52 salmeterol HFA MDI 52 PPCM 52 thyrotropin levels 52 A1c levels 52 adrenalectomy 52 JETSTREAM G3 52 mcg ml 52 flutamide 52 preserved ejection fraction 52 heterozygotes 52 pooled comparator 52 % CI #.#-#.# [006] 52 pegylated interferon alfa 2b 52 tumor necrosis 52 antiarrhythmic drug 52 external genital lesions 52 #:#-# [033] 52 nonfasting 52 apolipoprotein B 52 glycemia 52 fasting triglyceride levels 52 pentoxifylline 52 carotid revascularization 52 circulating IGF 52 abdominal irradiation 52 Troponin T 52 somatosensory evoked potentials 52 fosbretabulin 52 coronary stenoses 52 paraprotein 52 densitometry 52 Infarct 52 mg BID dose 52 recurrent glioblastoma multiforme 52 postoperative infection 52 unresectable HCC 52 intratumoral 52 dosage regimens 52 glycated hemoglobin 52 risk reducing salpingo 52 Kinoid 52 globulin 52 receiving ISENTRESS 52 induced sputum 52 Pharmacokinetic parameters 52 mesilate 52 experienced virologic failure 52 ALT flares 52 spirometric 52 percutaneous biopsy 52 peak VO2 52 ejection fractions 52 carotid stenosis 52 Pharmacodynamics 52 Hcy 52 immunostaining 52 cerebral oxygenation 52 pCR 52 inotropic agents 52 Teriparatide 52 hyperintensities 52 thyroid stimulating hormone 52 inhaled corticosteroids ICS 52 gadolinium enhanced 52 #mg BID [001] 52 osteopenic 52 Subgroup analysis 52 contractile function 52 EDSS score 52 intradermal injections 52 reactive hyperemia 52 #OHD levels 52 Tasigna prolongs 52 serum PSA 52 transaminase levels 52 blood Phe levels 52 dehydroepiandrosterone sulfate 52 iNO 52 mutated K ras 52 Myeloproliferative Neoplasms 52 oral hypoglycemic agents 52 neoplasias 52 #.#ng/ml 51 platelet inhibition 51 myocardial ischaemia 51 femoral neck BMD 51 Postoperative complications 51 #mg BID [003] 51 Calcium intake 51 pharmacodynamic PD 51 eplerenone 51 #mmHg [002] 51 vecuronium 51 apoB 51 cefotaxime 51 inhibitor RG# 51 diastolic pressures 51 intravitreal bevacizumab 51 Complication rates 51 carcinoembryonic antigen 51 baroreceptor 51 prostate cancer PCa 51 nM 51 serum parathyroid hormone 51 aminotransferase levels 51 TWYNSTA 51 antidiabetic medications 51 Adenomas 51 postprandial glycemia 51 FXIII 51 glucuronide 51 lymph node metastasis 51 gestational hypertension 51 Biphasic 51 non hematological toxicities 51 fructose intolerance 51 Hemospan R 51 parasitaemia 51 EuroSCORE 51 QRS interval 51 nonfasting triglyceride levels 51 RAPAFLO R 51 vesicoureteral reflux 51 VAPRISOL 51 tachyarrhythmias 51 BrachySil TM 51 #F FDG 51 CIMZIA TM certolizumab pegol 51 gastric pH 51 ERalpha 51 electrical cardioversion 51 systolic blood pressures 51 #mg/m# [002] 51 CLA supplementation 51 micromoles 51 irbesartan 51 adjunctive placebo 51 metformin sulphonylurea 51 ACE inhibitor ramipril 51 HAQ DI 51 hs CRP 51 tapentadol ER 51 vasoactive 51 alpha1 51 aOR 51 androgen ablation 51 coadministration 51 exogenous insulin 51 generalized edema 51 administered intranasally 51 seminal vesicle invasion 51 extracorporeal circulation 51 albumin excretion rate 51 #mg/day [002] 51 postoperative mortality 51 pharmacokinetic parameters 51 Cypher Stent 51 postoperative morbidity 51 recurrent UTI 51 glomerular 51 serum triglyceride 51 endometrial thickness 51 pulmonary artery pressure 51 renal cysts 51 metabolite concentrations 51 receiving prophylactic anticoagulation 51 alanine transaminase 51 cerebral oxygen saturation 51 busulfan 51 myocardial fibrosis 51 intestinal mucosal 51 TMP SMX 51 restenosis reblockage 51 hematologic abnormalities 51 glucose concentrations 51 CVD mortality 51 nondiabetic 51 homozygotes 51 cytopenias 51 hypervolemic 51 QRS duration 51 NIDDM 51 nanograms milliliter 51 opioid naïve 51 ritonavir boosted 51 TIMP 51 thrombocytosis 51 anti HBs 51 urinary excretion 51 INCB# [003] 51 QTc 51 Cystatin C 51 plasma uric acid 51 oxygen desaturation 51 endogenous EPO 51 thiazide 51 NIH CPSI 51 urinary oxalate 51 tryptase 51 CYPHER Stent 51 #mm Hg 51 subclinical hypothyroidism 51 lumbar spine bone 51 Technosphere ® 51 serum prostate 51 Decitabine 51 pulmonary arterial 51 dobutamine 51 HLA DR4 51 systemic bioavailability 51 receiving XGEVA 51 selective modulator 51 glucose insulin 51 endogenous glucose 51 valvulopathy 51 azacytidine 51 mcg dose 51 serum uric acid sUA 51 retinol binding protein 51 hypercholesterolemic patients 51 airway hyperresponsiveness 51 #ß 51 min -1 51 guanfacine extended release 51 Intrathecal 51 cerebrovascular accidents 51 normal ULN 51 Hp2 2 51 LNG IUS 51 TAXUS Express Stent 51 carotid plaques 51 inhaled budesonide 51 BALF 51 prevalent vertebral fracture 51 APIDRA R 51 OPCAB 51 C telopeptide 51 multivariable analysis 51 LEXIVA r 51 Pegylated Liposomal Doxorubicin 51 oxyhemoglobin 51 nonvertebral fracture 51 perioperative complications 51 nondiabetics 51 aspartate 51 teriflunomide 51 β blocker 51 sUA levels 51 Hepatotoxicity 51 dosing frequency 51 micromolar 51 retransplantation 51 Sumatriptan OS 51 hypercapnia 51 diuretics beta blockers 51 CHAMPION PCI 51 anthracycline chemotherapy 51 GI motility 51 Humate P 51 radiographic findings 51 multivessel disease 51 severe hypoglycemic episodes 51 acute myocardial infarctions 51 zonisamide SR 51 gastric cardia 51 c reactive protein 51 prucalopride 51 CD4 + cell 51 cholestasis 51 steroid dexamethasone 51 verteporfin 51 doxorubicin cyclophosphamide 51 cardiac troponin 51 hepatic enzymes 51 radioiodine therapy 51 Urinalysis 51 stimulates insulin secretion 51 bronchodilatory 51 receptor blocker 51 phototoxicity 51 #mg/dl 51 neurologic progression 51 urine NGAL 51 achieving PASI